{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029889","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.573485+00:00","generated_at":"2026-06-04T22:49:58.971374+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enanta shareholders approve 975,000-share increase to 2019 Equity Incentive Plan","bullets":["Stockholders approved amendment to 2019 Equity Incentive Plan, increasing share reserve by 975,000 shares.","Re-elected Class II directors Yujiro S. Hata, Kristine Peterson, and Terry C. Vance.","Advisory say-on-pay vote passed with 12,306,697 votes for (79.4% of votes cast).","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029889","json":"https://secwatch.observer/filing/0000950170-24-029889.json","markdown":"https://secwatch.observer/filing/0000950170-24-029889.md","text":"https://secwatch.observer/filing/0000950170-24-029889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024029889/0000950170-24-029889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024029889/enta-20240306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:49:58.971374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ec1c9ebe2a789f810f8a4a54adc4b1a2bd53ca3","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Approve an Amendment to Our 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 975,000 shares at the 2024-03-06 meeting.","evidence_excerpt":"Proposal No. 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares. Votes For Votes Against Abstain Broker Non-Votes 8,076,566 7,421,300 21,356 1,156,034","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024029889/0000950170-24-029889-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-06"}],"fact_type":"shareholder_vote"},{"claim_id":"861b9da95ae2fa08752fc2442c1cdf9e6fe1b603","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2024-03-06 meeting.","evidence_excerpt":"Proposal No. 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a “say-on-pay” vote. Votes For Votes Against Abstain Broker Non-Votes 12,306,697 3,196,342 16,183 1,156,034","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024029889/0000950170-24-029889-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-06"}],"fact_type":"shareholder_vote"},{"claim_id":"e74a9a0d838962f038dd32f49252654cd914de22","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2024 Fiscal Year at the 2024-03-06 meeting.","evidence_excerpt":"Proposal No. 4: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2024 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2024. Votes For Votes Against Abstain Broker Non-Votes 14,571,800 27,373 2,076,083 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024029889/0000950170-24-029889-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-06"}],"fact_type":"shareholder_vote"},{"claim_id":"f3862dd6b416bf5beeeb2809809856c8f2c970d4","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Election of Three Class II Directors at the 2024-03-06 meeting.","evidence_excerpt":"Proposal No. 1: To Elect Three Class II Directors to Serve until the 2027 Annual Meeting or until their respective successors are elected and qualified. The stockholders re-elected the following individuals as Class II directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Yujiro S. Hata 13,127,063 2,392,002 1,156,191 Kristine Peterson 12,994,324 2,524,741 1,156,191 Terry C. Vance 12,169,732 3,209,519 1,296,005","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024029889/0000950170-24-029889-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-06"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}